期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 25, 期 9, 页码 1825-1831出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2019.05.023
关键词
Thrombocytopenia; Allogeneic stem cell transplantation; Thrombopoietin receptor agonists
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), and some studies with very small numbers of cases have reported their potential efficacy in the allo-SCT setting. The present retrospective study evaluated the safety and efficacy of TPO-RAs in 86 patients with persistent thrombocytopenia after allo-HSCT. Sixteen patients (19%) had isolated thrombocytopenia (PT), and 71 (82%) had secondary failure of platelet recovery (SFPR). TPO-RA therapy was started at a median of 127 days (range, 27 to 1177 days) after allo-SCT. The median initial and maximum administered doses were 50 mg/day (range, 25 to 150 mg/day) and 75 mg/day (range, 25 to 150 mg/day), respectively, for eltrombopag and 1 mu g/kg (range, 1 to 7 mu g/kg) and 5 mu g/kg (range, 1 to 10 mu g/kg), respectively, for romiplostin. The median platelet count before initiation of TPO-RA therapy was 14,000/mu L (range, 1000 to 57,000/mu L). Platelet recovery to >= 50,000/mu L without transfusion support was achieved in 72% of patients at a median time of 66 days (range, 2 to 247 days). Eighty-one percent of the patients had a decreased number of megakaryocytes before treatment, showing a slower response to therapy (P=.011). The median duration of treatment was 62 days (range, 7 to 700 days). Grade 3-4 adverse events (hepatic and asthenia) were observed in only 2% of the patients. At last follow-up, 81% of patients had discontinued TPO-RAs and maintained response, and 71% were alive. To our knowledge, this is the largest series analyzing the use of TPO-RAs after allo-SCI reported to date. Our results support the efficacy and safety in this new setting. Further prospective trials are needed to increase the level of evidence and to identify predictors of response. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据